401518-11-4 Usage
General Description
N-Boc-N,N-Bis{2-[(methanesulfonyl)oxy]ethyl}amine is a chemical compound with the molecular formula C11H23NO7S2. It is a reagent used in organic synthesis, particularly in the protection and deprotection of amines. The compound is a derivative of Boc-protected amines, which are commonly used in peptide synthesis. N-Boc-N,N-Bis{2-[(methanesulfonyl)oxy]ethyl}amine is particularly useful for the synthesis of complex molecules and pharmaceutical compounds due to its stability and compatibility with a wide range of reaction conditions. It is also known for its high selectivity and efficiency in protecting amine functional groups, making it a valuable tool for chemical research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 401518-11-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,1,5,1 and 8 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 401518-11:
(8*4)+(7*0)+(6*1)+(5*5)+(4*1)+(3*8)+(2*1)+(1*1)=94
94 % 10 = 4
So 401518-11-4 is a valid CAS Registry Number.
InChI:InChI=1/C11H23NO8S2/c1-11(2,3)20-10(13)12(6-8-18-21(4,14)15)7-9-19-22(5,16)17/h6-9H2,1-5H3
401518-11-4Relevant articles and documents
AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR
-
Paragraph 0198, (2021/05/29)
A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.
Highly potent PDE4 inhibitors with therapeutic potential
Ochiai, Hiroshi,Ohtani, Tazumi,Ishida, Akiharu,Kusumi, Kensuke,Kato, Masashi,Kohno, Hiroshi,Odagaki, Yoshihiko,Kishikawa, Katuya,Yamamoto, Susumu,Takeda, Hiroshi,Obata, Takaaki,Nakai, Hisao,Toda, Masaaki
, p. 4645 - 4665 (2007/10/03)
Synthesis and biological evaluation of piperidine derivatives is reported. The hypothesis that the dose-limiting side effects of PDE4 inhibitors could be mediated via the central nervous system prompted us to design and synthesize a hydrophilic piperidine